Intensity Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.54 million compared to USD 7.58 million a year ago. Basic loss per share from continuing operations was USD 1.38 compared to USD 2.22 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.925 USD | 0.00% | +1.16% | -54.20% |
Mar. 14 | Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 03 | Intensity Therapeutics Gets FDA Green Light for Phase 3 Study | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.20% | 53.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- INTS Stock
- News Intensity Therapeutics, Inc.
- Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023